Profile data is unavailable for this security.
About the company
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.
- Revenue in INR (TTM)5.52bn
- Net income in INR-119.17m
- Incorporated1984
- Employees1.09k
- LocationPanacea Biotec LtdB-1 Extn / G-3Mathura Road, Mohan Co-opIndlEstateNEW DELHI 110044IndiaIND
- Phone+91 1 141679000
- Fax+91 1 141679075
- Websitehttps://www.panaceabiotec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valiant Laboratories Ltd | 1.82bn | 3.40m | 6.08bn | -- | 333.21 | 2.57 | 265.72 | 3.34 | 0.42 | 0.42 | 49.55 | 54.51 | -- | -- | -- | -- | -- | -- | -- | -- | 7.58 | -- | 0.187 | -- | 7.41 | -133.11 | 0.2446 | -- | -45.48 | -- | -98.83 | -- | -- | -- |
| IND Swift Laboratories Ltd | 12.81bn | 3.07bn | 6.34bn | 1.50k | 2.06 | 0.6803 | 1.76 | 0.4947 | 51.99 | 51.99 | 216.90 | 157.64 | 0.857 | 3.45 | 3.80 | -- | 20.58 | 5.00 | 25.67 | 6.13 | 39.47 | 42.82 | 24.02 | 8.52 | 2.94 | 1.70 | 0.0175 | -- | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Albert David Ltd | 3.62bn | 754.20m | 6.58bn | 1.27k | 8.72 | 1.72 | 8.00 | 1.81 | 132.16 | 132.16 | 635.16 | 671.05 | 0.7868 | 2.67 | 12.15 | -- | 16.37 | 10.00 | 20.85 | 13.15 | 65.30 | 61.03 | 20.81 | 11.87 | 3.31 | 124.70 | 0.0086 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Medicamen Biotech Ltd | 1.71bn | 126.93m | 6.61bn | 388.00 | 53.18 | -- | 36.41 | 3.88 | 9.78 | 9.78 | 131.89 | -- | -- | -- | -- | 4,398,250.00 | -- | 7.17 | -- | 10.44 | 46.88 | 33.85 | 6.58 | 10.87 | -- | 4.76 | -- | 8.61 | 22.02 | 4.77 | -0.3555 | 7.98 | -4.21 | 0.00 |
| Nectar Lifesciences Ltd | 16.86bn | 49.95m | 7.48bn | 1.59k | 145.00 | 0.6995 | 11.38 | 0.4437 | 0.23 | 0.23 | 79.16 | 47.68 | 0.7697 | 1.74 | 5.12 | -- | 0.228 | -0.2956 | 0.3969 | -0.541 | 28.68 | 18.39 | 0.2963 | -0.4052 | 0.5907 | 1.06 | 0.3728 | -- | 10.63 | -9.54 | 120.65 | -36.29 | -5.06 | -- |
| Sakar Healthcare Ltd | 1.51bn | 124.73m | 7.52bn | 297.00 | 56.66 | -- | 25.74 | 4.98 | 6.10 | 6.10 | 73.58 | -- | -- | -- | -- | 5,082,286.00 | -- | 6.35 | -- | 7.59 | 46.18 | 44.28 | 8.26 | 10.84 | -- | 2.40 | -- | -- | 4.00 | 20.23 | -16.30 | 27.31 | 56.31 | -- |
| Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.45bn | 1.06k | 39.70 | -- | 17.23 | 1.70 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
| Panacea Biotec Ltd | 5.52bn | -119.17m | 8.45bn | 1.09k | -- | -- | 16.43 | 1.53 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 9.09bn | 940.00 | 36.97 | -- | 34.60 | 4.12 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
| Vimta Labs Ltd | 3.20bn | 413.41m | 10.73bn | 1.37k | 26.35 | -- | 14.22 | 3.35 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 11.29bn | 38.00 | 119.87 | 43.44 | 125.68 | 25.06 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.81bn | 933.05m | 11.37bn | 1.70k | 12.18 | 1.92 | 10.94 | 1.96 | 46.58 | 46.58 | 289.81 | 295.98 | 0.9017 | 3.78 | 3.90 | -- | 14.49 | 13.95 | 16.61 | 16.54 | 52.06 | 51.21 | 16.07 | 14.71 | 4.01 | 60.95 | 0.0018 | -- | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Holder | Shares | % Held |
|---|---|---|
| Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 144.00 | 0.00% |
